Scolaris Content Display Scolaris Content Display

Adapted QUOROM (quality of reporting of meta‐analyses) flow‐chart of study selection
Figures and Tables -
Figure 1

Adapted QUOROM (quality of reporting of meta‐analyses) flow‐chart of study selection

Comparison 1 Adverse events, Outcome 1 Incidence of xerostomia (dry mouth and hypogeusia).
Figures and Tables -
Analysis 1.1

Comparison 1 Adverse events, Outcome 1 Incidence of xerostomia (dry mouth and hypogeusia).

Comparison 1 Adverse events, Outcome 2 Reduction of blood pressure.
Figures and Tables -
Analysis 1.2

Comparison 1 Adverse events, Outcome 2 Reduction of blood pressure.

Comparison 2 Decrease in uptake of technetium‐99m by parotid gland at 12 months, Outcome 1 Decrease in uptake of technetium‐99m by parotid gland at 12 m.
Figures and Tables -
Analysis 2.1

Comparison 2 Decrease in uptake of technetium‐99m by parotid gland at 12 months, Outcome 1 Decrease in uptake of technetium‐99m by parotid gland at 12 m.

Comparison 2 Decrease in uptake of technetium‐99m by parotid gland at 12 months, Outcome 2 Decrease in uptake of technetium‐99m by mandibular gland at 12 m.
Figures and Tables -
Analysis 2.2

Comparison 2 Decrease in uptake of technetium‐99m by parotid gland at 12 months, Outcome 2 Decrease in uptake of technetium‐99m by mandibular gland at 12 m.

Comparison 3 Radioactive iodine dose, Outcome 1 Decrease in uptake of technetium‐99m by parotid gland at 3 m.
Figures and Tables -
Analysis 3.1

Comparison 3 Radioactive iodine dose, Outcome 1 Decrease in uptake of technetium‐99m by parotid gland at 3 m.

Comparison 3 Radioactive iodine dose, Outcome 2 Decrease in uptake of technetium‐99m by submandibular glands at 3 m.
Figures and Tables -
Analysis 3.2

Comparison 3 Radioactive iodine dose, Outcome 2 Decrease in uptake of technetium‐99m by submandibular glands at 3 m.

Table 1. Study populations data

study ID

intervention

[n] screened

[n] randomised

[n] safety

[n] ITT

[n] finishing study

comments

Bohuslavizki 1998b

amifostine (I)

placebo (C)

I: 25

C: 25

Total: 50

I: 25

C: 25

Total: 50

I: 25

C: 25

Total: 50

I: not mentioned

C: not mentioned

I: 25

C: 25

Total: 50

none

Kim 2008

amifostine (I)

placebo (C)

I: 42

C: 38

Total: 80

I: 42

C: 38

Total: 80

I: 42

C: 38

Total: 80

I: not mentioned

C: not mentioned

I: 42

C: 38

Total: 80

none

ITT: intention‐to‐treat

Figures and Tables -
Table 1. Study populations data
Comparison 1. Adverse events

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Incidence of xerostomia (dry mouth and hypogeusia) Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2 Reduction of blood pressure Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

Figures and Tables -
Comparison 1. Adverse events
Comparison 2. Decrease in uptake of technetium‐99m by parotid gland at 12 months

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Decrease in uptake of technetium‐99m by parotid gland at 12 m Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Decrease in uptake of technetium‐99m by mandibular gland at 12 m Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 2. Decrease in uptake of technetium‐99m by parotid gland at 12 months
Comparison 3. Radioactive iodine dose

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Decrease in uptake of technetium‐99m by parotid gland at 3 m Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2 Decrease in uptake of technetium‐99m by submandibular glands at 3 m Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

Figures and Tables -
Comparison 3. Radioactive iodine dose